In this article, we catch up with the past. Just to make sure that we have everyone on the same virtual page. Acomplia (generic name rimonabant) has been an authorised medication in the EU since June 2006 for use in …

Acomplia produced disappointing results in slowing progression of coronary artery disease in patients and it significantly raised the risk of anxiety and depression, according to a report in the April 2 issue of the Journal of the American Medical Association.
More …

Pondering over weight loss? With obesity spreading far and wide, entrapping young and old alike in its ambit, it is important to find a solution to this health hazard. Weight loss pills which have made their presence felt in the …

A study in rats suggests that the anti-obesity drug rimonabant may also reduce liver damage and improve cholesterol levels.

Rimonabant is available in Europe under the brand name Acomplia but is not approved for use in the United States.

French researchers at …